Evolving Cognitive Dysfunction in Children with Neurologically Stable Opsoclonus-Myoclonus Syndrome.
cognitive dysfunction
neurodevelopment
opsoclonus–myoclonus syndrome
Journal
Children (Basel, Switzerland)
ISSN: 2227-9067
Titre abrégé: Children (Basel)
Pays: Switzerland
ID NLM: 101648936
Informations de publication
Date de publication:
19 Aug 2020
19 Aug 2020
Historique:
received:
21
07
2020
revised:
09
08
2020
accepted:
13
08
2020
entrez:
23
8
2020
pubmed:
23
8
2020
medline:
23
8
2020
Statut:
epublish
Résumé
Cognitive and acquired neurodevelopmental deficits have been reported in children with opsoclonus-myoclonus syndrome (OMS) and are known to be associated with more severe and relapsing disease course. However, there is a paucity of data regarding cognitive dysfunction in children with stable neurological disease. We report three children with OMS and evolving cognitive dysfunction in the context of a mild disease course. The children's ages at disease onset were between 17 and 35 months and they were followed up for 4-10 years. Neuroblastoma was identified in one child. OMS severity scores ranged between 8 and 12/15 at presentation. They underwent immunotherapy and all were in remission by 7 months (range 4-13 months), with treatment maintained for 1 year. One child remained relapse-free, while two others had one clinical relapse each and were immunotherapy-responsive again. In all cases, evolving cognitive dysfunction was reported despite being in remission and stable off treatment for a median of 20 months (range of 12-31 months; two OMS scores of 0/15 and one of 2/15). In children with OMS who have completed treatment and have made full or near full neurological recovery, concerns remain regarding long-term outcome in terms of future learning and cognitive development.
Identifiants
pubmed: 32824925
pii: children7090103
doi: 10.3390/children7090103
pmc: PMC7552772
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Brain. 2011 Aug;134(Pt 8):2197-221
pubmed: 21784775
Curr Opin Pediatr. 2010 Dec;22(6):745-50
pubmed: 20871403
Neurology. 2018 Aug 21;91(8):e714-e723
pubmed: 30045961
Eur J Paediatr Neurol. 2010 Mar;14(2):156-61
pubmed: 19423368
J Pediatr Psychol. 2009 May;34(4):406-18
pubmed: 18794190
Pediatr Neurol. 2014 Oct;51(4):515-21
pubmed: 25266614
Pediatrics. 2005 Oct;116(4):901-7
pubmed: 16199699
Dev Med Child Neurol. 2015 Mar;57(3):265-72
pubmed: 25290446
Annu Rev Psychol. 2009;60:173-96
pubmed: 19035823
Neurology. 2004 May 11;62(9):1526-32
pubmed: 15136676
Behav Neurol. 2017;2017:1463570
pubmed: 29434433
J Pediatr Oncol Nurs. 2005 Jan-Feb;22(1):8-19
pubmed: 15574722
Dev Med Child Neurol. 2020 Jul 22;:
pubmed: 32696984
Pediatrics. 2011 Aug;128(2):e388-94
pubmed: 21788225
Front Neurosci. 2011 Mar 11;5:25
pubmed: 21441995
J Pediatr. 2001 Oct;139(4):552-9
pubmed: 11598603
Pediatrics. 2008 Jun;121(6):1155-64
pubmed: 18519485
Pediatrics. 2002 Jan;109(1):86-98
pubmed: 11773546
Paediatr Perinat Epidemiol. 2009 May;23(3):186-98
pubmed: 19775380
BJOG. 2018 Jan;125(1):16-25
pubmed: 29024294